Effect of a new cholecystokinin antagonist (FK 480) on gene expression of cholecystokinin and secretin in rat intestine.
The effects of a new cholecystokinin (CCK) antagonist (FK 480; 0.1 mg/kg per day given by intragastric administration to rats for 3 days) on the expression of the CCK and secretin genes, plasma CCK immunoreactivity, and CCK content in the intestinal mucosa were examined. FK 480 increased the level of CCK mRNA in the intestine to 1.7 times the level in control rats, but did not affect the level of secretin mRNA. It did not increase plasma CCK immunoreactivity or CCK content in the intestinal mucosa. These results suggest that the ingested FK 480 directly increased CCK mRNA level in the intestine and produced a dissociation between the synthesis and release of CCK.
Funakoshi
A
A
Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka, Japan.
Miyasaka
K
K
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000235:genetics*; D015870:Gene Expression / Q000187:drug effects*; D007211:Indoles / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000378:metabolism; D008297:Male; D012333:RNA, Messenger / Q000187:drug effects* / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D012633:Secretin / Q000235:genetics*
D001570:Benzodiazepinones; D007211:Indoles; D012333:RNA, Messenger; D012633:Secretin; C082966:FR 120480; D002766:Cholecystokinin